The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
P.O. Box 3453
Peabody, MA 01961-3453 USA
Established in 1999, the mission of The Progeria Research Foundation (PRF) is to discover a cure and effective treatment for Hutchinson-Gilford progeria syndrome (Progeria or HGPS) and its aging related disorders by funding medical research, providing research-related programs, and educating the families, their physicians, scientists and the general public. Progeria (a word that comes from the Greek meaning "prematurely old") is a fatal medical disorder with a life expectancy of about 13 years. Within the first 2 years of life, children afflicted with progeria fail to develop properly; they begin to display physiological characteristics typically associated with advanced age: loss of body fat and hair, joint stiffness, hip dislocation, and rapid progression of atherosclerosis. Research on progeria, particularly on its fatal outcome, heart disease, will benefit not only these special children, but also millions of people who suffer from heart disease and other aging related conditions. PRF is a leading resource for information and resources on progeria. PRF runs its own cell & tissue bank, medical & research database, and diagnostic testing program, and provides funding for research. Additionally, PRF runs an international patient registry and holds scientific workshops jointly with the National Institutes of Health.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.